Overview of other systemic MHT
Other options for oral menopausal hormone therapy (MHT) are:
These therapies can be used for postmenopausal individuals. They are not suitable for perimenopausal individuals because they can cause breakthrough bleeding.
Although they cause less breast tenderness and uterine bleeding than systemic estrogen and progestogen, these therapies may be less effective in controlling vasomotor symptoms.
For a suggested approach to starting menopausal therapy, including tibolone and conjugated estrogens+bazedoxifene, see Formulations of combined hormonal contraception available in Australia.